Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | PDE5A | O76074 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3692130 | 0.90 | MTNR1A (0.51) | MTNR1AMTNR1BKCNH2IRAK4PDE5A | |
| SCHEMBL5648051 | 0.87 | KCNH2 (0.55) | MCHR1MTNR1AMTNR1BKCNH2 | |
| SCHEMBL3691384 | 0.85 | KCNH2 (0.58) | MTNR1AMTNR1BKCNH2PDE5ASLC2A1 | |
| SCHEMBL3689154 | 0.85 | PDE5A (0.56) | MCHR1MTNR1AMTNR1BKCNH2PDE5A | |
| SCHEMBL3695760 | 0.85 | CLK4 (0.46) | MTNR1AMTNR1BKCNH2IRAK4 | |
| SCHEMBL3697253 | 0.79 | MTNR1A (0.45) | MTNR1AMTNR1BKCNH2IRAK4SLC2A1 | |
| SCHEMBL3694275 | 0.78 | MTNR1B (0.54) | MTNR1AMTNR1BIRAK4 | |
| SCHEMBL3689911 | 0.77 | MTNR1A (0.46) | MCHR1MTNR1AMTNR1BKCNH2IRAK4 | |
| SCHEMBL5648828 | 0.77 | MTNR1A (0.46) | MCHR1MTNR1AMTNR1BKCNH2IRAK4 | |
| SCHEMBL3695637 | 0.76 | MTNR1B (0.40) | MCHR1MTNR1AMTNR1BKCNH2IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2239260-A1 | Novel compounds with antibacterial activity | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2010-10-13 | — | — | EP | disclosed |
| US-7223776-B2 | Compounds with anti-bacterial activity | MORPHOCHEM AG (DE) | 2007-05-29 | — | — | US | disclosed |
| US-7223776-B2 | Compounds with anti-bacterial activity | MORPHOCHEM AG (DE) | 2007-05-29 | — | — | US | disclosed |
| US-7223776-B2 | Compounds with anti-bacterial activity | MORPHOCHEM AG (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20060040949-A1 | Novel compounds with antibacterial activity | MORPHOCHEM AG | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040949-A1 | Novel compounds with antibacterial activity | MRPL21, Q6ZSR9, MRPL19 | MCHR1 4271/4885MTNR1A 3313/4885MTNR1B 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.